Please wait a minute...
Reviews in Cardiovascular Medicine  2020, Vol. 21 Issue (4): 531-540     DOI: 10.31083/j.rcm.2020.04.154
Special Issue: Heart failure pathogenesis and management: heart failure with preserved ejection fraction
Review Previous articles | Next articles
Epidemiology and pathogenesis of heart failure with preserved ejection fraction
Nandini Nair1, *()
1Division of Cardiology, Department of Medicine, Texas Tech Health Sciences Center, Lubbock, 79430, TX, USA
Download:  PDF(312KB)  ( 2724 ) Full text   ( 269 )
Export:  BibTeX | EndNote (RIS)      
Heart failure (HF) is a complex syndrome that affects approximately 6.5 million adults in the United States. About half of the 6.5 million adults with HF are estimated to be individuals with heart failure with preserved ejection fraction (HFpEF). It is a common cause for poor quality of life, increased health-care resource utilization, and early mortality. HF incidence has risen to epidemic proportions in the recent years. This review attempts to address the epidemiology and pathophysiology of HFpEF. The incidence of HFpEF increased from 48% to 57% from 2000 to 2007 with a slight decrease in 2010 to 52%. The temporal trends in heart failure show an overall stable incidence of HF over the last two decades with increasing incidence of HFpEF and decreasing HFrEF incidence. Many etiologies contribute to the development of HFpEF which makes the treatment very challenging. Pathophysiology of HFpEF is multifaceted stemming from several disease-specific aspects of inflammation and endothelial function, cardiomyocyte hypertrophy and fibrosis, ventricular-vascular uncoupling, pulmonary hypertension and chronotropic incompetence. Hence identifying the risk factors and etiologies is imperative to achieve optimal outcomes in this population. Newer insights into myocardial remodeling have led to an interesting finding of abnormal fibroblasts in HFpEF which are apoptosis resistant and initiate the development of an abnormal myocardial matrix resulting in initiation and progression of the disease. Upregulation of ROS has also been implicated in HFpEF. Further investigation could provide new avenues to target therapeutics specifically to stop initiation and progression of fibrosis.
Key words:  HFpEF      diastolic dysfunction      pathophysiology      oxidative stress      myocardial remodeling     
Submitted:  28 July 2020      Revised:  25 October 2020      Accepted:  27 October 2020      Published:  30 December 2020     
*Corresponding Author(s):  Nandini Nair     E-mail:

Cite this article: 

Nandini Nair. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Reviews in Cardiovascular Medicine, 2020, 21(4): 531-540.

URL:     OR

[1] Nidhi Madan, Dinesh Kalra. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 181-190.
[2] Adila A Hamid, Amilia Aminuddin, Mohd Heikal Mohd Yunus, Jaya Kumar Murthy, Chua Kien Hui, Azizah Ugusman. Antioxidative and anti-inflammatory activities of Polygonum minus: a review of literature[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 275-287.
[3] Jing Jin, Yufeng Liu, Lihong Huang, Hong Tan. Advances in epigenetic regulation of vascular aging[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 19-25.
[4] Muhammad Asrar ul Haq, Chiew Wong, David L. Hare. Heart Failure With Preserved Ejection Fraction: An Insight Into Its Prevalence, Predictors, and Implications of Early Detection[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 20-27.
[5] Adam Whaley-Connell, Peter A. McCullough, James R. Sowers. The Role of Oxidative Stress in the Metabolic Syndrome[J]. Reviews in Cardiovascular Medicine, 2011, 12(1): 21-29.
[6] Gregg C. Fonarow. Acute Decompensated Heart Failure: Challenges and Opportunities[J]. Reviews in Cardiovascular Medicine, 2007, 8(S5): 3-12.
[7] Kambiz Yazdani, Suraj Maraj, Aman M. Amanullah. Differentiating Constrictive Pericarditis from Restrictive Cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2005, 6(2): 61-71.
[8] Tasneem Z. Naqvi. Diastolic Function Assessment Incorporating New Techniques in Doppler Echocardiography[J]. Reviews in Cardiovascular Medicine, 2003, 4(2): 81-99.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Prakash C. Deedwania. Management of Patients With Stable Angina and Type 2 Diabetes[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 105 -113 .
[5] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[6] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[7] George L. Smith. Appropriate Use Criteria: The Gold Standard, or a Mechanism for the Derogation of Clinical Judgment?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 105 .
[8] Prabhjot Singh Nijjar, Anoop Parameswaran, Aman M. Amanullah. Evaluation of Anomalous Aortic Origins of the Coronaries by 64-Slice Cardiac Computed Tomography[J]. Reviews in Cardiovascular Medicine, 2007, 8(3): 175 -181 .
[9] . SELF-ASSESSMENT POST-TEST[J]. Reviews in Cardiovascular Medicine, 2006, 7(S2): 51 -52 .
[10] Alice K. Jacobs. Gender Differences in Coronary Revascularization: Does Age Make a Difference?[J]. Reviews in Cardiovascular Medicine, 2004, 5(1): 68 -70 .